Medication Guide

Prescription Info

Instructions for Use

Treating patients
on HUMIRA (adalimumab)? Consider a biosimilar called HADLIMA. HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
Limitations of Use:
The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers. Dov, a real patient
with moderately to
severely active ulcerative
colitis who switched from HUMIRA (adalimumab)
to HADLIMA, an
FDA-approved
interchangeable
biosimilar to HUMIRA.¹ Cost and coverage
for HADLIMA is
dependent on the
terms and conditions
of individual insurance
benefits, including any
applicable deductible,
co-insurance, or
co-payment.Based on analysis of
actual patient claims
processed from July
2023 to August 2024,
with the average
out-of-pocket costs
being $215 vs $48 for
HUMIRA and HADLIMA, respectively.² Consider which patients may benefit from switching
to HADLIMA today.